J&J revealed that its proposed prepackaged bankruptcy plan for Red River Talc LLC was not approved by the U.S. Bankruptcy Court for the Southern District of Texas. Instead of appealing, J&J plans to ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...

New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Effective from 1 April 2025, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S and Totalkredit A/S will be adjusted. The new coupon rates will apply from 1 April 2025 to 30 ...

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...

Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along ...